PRECISION ONCOLOGY

Developing antibody based therapies directed to Cancer-specific targets

 

Press Release

CellmAbs Announces Patent Assignment and Licensing Agreement with BioNTech 

According to the Press Release, “Under the terms of the agreement, BioNTech will acquire one of CellmAbs’ pre-clinical antibody candidates and additional ADC technology. CellmAbs will be receiving upfront and near-term payments and may be eligible to receive several hundred million US Dollars in milestone payments. The deal also includes tiered royalty payments.”

 

NOVEL HUMANIZED MONOCLONAL ANTIBODIES DESIGNED TO RECOGNIZE AND TARGET CANCER-SPECIFIC ANTIGENS ON SOLID TUMORS

 
 
ADC, Bispecific and CAR-T

For the first time ever, researchers at CellmAbs have generated humanized antibodies with unprecedented specificity, and binding capability to glycan targets only expressed on cancer cells.

It is now possible to develop anti-cancer therapies in different modalities, capable of effectively addressing several types of solid tumors and in several stages of Cancer.

We have generated a panel of novel mAbs with different features to enable fine-tuning of targeted therapies:

  • Binding;

  • Affinity;

  • Internalization (low, intermediate and high).